ACAD: ACADIA Pharmaceuticals Inc. Company Sales Revenue
ACADIA Pharmaceuticals is integrating ESG principles into neuropharmacology, adhering to research ethics and laboratory sustainability. The company's implementation history demonstrates daily inflow dynamics, where 1.20 reflects the latest metric value. Stable sales of CNS drugs protect profitability from macroeconomic volatility, while an impeccable reputation among psychiatrists confirms its status as a creator of unique medical solutions.
%20Company%20Revenue&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_ACAD_-_ACADIA-Pharmaceuticals_-_Company-Revenue "ACADIA Pharma (ACAD): Company Annual Revenue from 07/04/2022 to 11/14/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for ACADIA Pharmaceuticals
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- company liabilities and liquidity data:
Total Debt to Capital ACADIA Pharmaceuticals|ACAD - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital ACADIA Pharma|ACAD - Company Debts|Debt to Book Value ACADIA Pharmaceuticals Inc.|ACAD - Company Long-Term Debts|Company Short-Term Debts ACADIA Pharmaceuticals|Quick Liquidity Indicator acadia-pharm.com
- net income and valuation multiples indicators:
ACAD - Net Profit|Expected Net Profit ACADIA Pharmaceuticals|ACAD - Price to Earnings Ratio|Forward P/E Multiple acadia-pharm.com|ACAD - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio ACADIA Pharmaceuticals Inc.|ACAD - Operating profit EBITDA|Net earnings per share for the last four quarters ACADIA Pharmaceuticals|ACAD - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months acadia-pharm.com|ACAD - Earnings growth in current year|Earnings growth forecast for next year ACADIA Pharmaceuticals
- company sales and revenue statistics:
Comprehensive company analysis:ACAD ACADIA Corp
Investors are assessing the potential of ACADIA Pharmaceuticals (ACAD) through the dynamics of actual cash inflows, where the metric's calculation logic captures the daily volume of drug sales prior to their capitalization in financial statements. By analyzing the ACADIA Pharmaceuticals (ACAD) sales chart, one can track the effectiveness of interactions with Medicare government funds and insurance companies, enabling the rapid identification of risks or growth in demand for neurological disorder therapies.
Key competitors
Revenue and Sales Volume Biogen Idec|Company Sales NBIX (Neurocrine Biosciences)|RGC (regencellbioscience.com) - Company Sales Revenue|Company Revenue Axsome Therapeutics, Inc. AXSM|XENE (Xenon Pharmaceuticals Inc.) - Company Annual Revenue|Viking Pharma - Revenue and Sales Volume|Company Sales Revenue SUPN (Supernus Corp)|CPRX: Revenue and Sales Volume|denalitherapeutics.com (DNLI) - Revenue and Sales Volume|Company Revenue Harmony Biosciences Holdings, Inc.|BHVN: Company Sales Revenue|Company Revenue Amylyx (AMLX)|Company Sales Trevi Corp TRVI|Revenue and Sales Volume PRAX (Praxis Precision Medicines)|Revenue and Sales Volume anavex.com AVXL|CeriBell - Revenue and Sales Volume|Prothena Corporation plc (PRTA) - Company Sales|ALEC: Revenue and Sales Volume|Company Total Revenue Annexon Biosciences Inc. (ANNX)|Company Sales OMER|Revenue and Sales Volume neurogene.com|Company Sales ACIU (AC Immune SA)|Company Total Sales VYGR|Revenue and Sales Volume NMRA (Neumora Therapeutics Inc)|Company Gross Revenue Scilex Holding Company, Inc. (SCLX)|Tevogen Bio Holdings - Revenue and Sales Volume|Alpha Cognition (ACOG) - Company Sales|CGTX: Revenue and Sales Volume|Inhibikase Therapeutics Inc (IKT) - Revenue and Sales Volume|Company Revenue Cassava|Company Revenue ASRT|Company Revenue Coya Therapeutics, Inc. (COYA)|Company Gross Revenue vistagen.com|Revenue and Sales Volume OVID (Ovid Therapeutics)|Revenue and Sales Volume Acumen Pharmaceuticals Inc. ABOS|CervoMed Inc - Revenue and Sales Volume|Alterity Therapeutics (ATHE) - Company Sales|CLNN: Revenue and Sales Volume|PepGen (PEPG) - Revenue and Sales Volume|JUNS (Jupiter Neurosciences Inc) - Revenue and Sales Volume|Company Sales Volume RLMD (Relmada Therapeutics Inc)|Company Revenue Annovis Bio Corp (ANVS)|gracetx.com - Company Sales Volume|Revenue and Sales Volume AIFF (Firefly Neuroscience, Inc)|ANEW Medical (KLTO) - Company Total Revenue|NRSN: Company Sales|RVPH - Revenue and Sales Volume|metaviatx.com (MTVA) - Company Revenue|NeurAxis Inc - Company Sales Revenue|Company Revenue Helius Medical Technologies, Inc.|Company Total Revenue Passage Bio Corp PASG|Revenue and Sales Volume NEUP|Revenue and Sales Volume Minerva Neurosciences Inc (NERV)|Revenue and Sales Volume ATHA (Athira)|ADXN - Company Sales|Alzamend - Revenue and Sales Volume|CYCN - Revenue and Sales Volume|PTIX: Revenue and Sales Volume|Company Sales Volume KTTA|CRGT (Cortigent Inc) - Revenue and Sales Volume|Avenue Therapeutics Inc (ATXI) - Company Gross Revenue|Revenue and Sales Volume BCLI|Revenue and Sales Volume caratherapeutics.com (CARA)|Chromocell Therapeutics Corp. - Company Sales|Company Sales Revenue ELYM|ITCI - Company Revenue|Company Annual Revenue LBPH|MRNS: Revenue and Sales Volume|nkgenbiotech.com - Company Sales Revenue|NRBO (NeuroBo Pharmaceuticals, Inc.) - Revenue and Sales Volume|Revenue and Sales Volume Sage Therapeutics Inc.|Company Revenue Neurotrope (SNPX)|TRVN (Trevena Inc) - Company Sales Revenue|Company Revenue Vigil Neuroscience, Inc. VIGL|WENA - Company Sales|Cerevel Therapeutics, Inc. - Revenue and Sales Volume
